Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03420469 · ClinicalTrials.gov registry record · Early Phase 1
Bupropion Stereoselective Disposition and CYP2D6-mediated Drug Interactions in Healthy Volunteers
A Early Phase 1 study, sponsored by Indiana University.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 28
- Enrollment target
NCT03420469 is a Early Phase 1 study that has completed, run by Indiana University. The registered enrollment target is 28 participants.
The verdict
NCT03420469, a Early Phase 1 study, has completed, sponsored by Indiana University.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 28 participants
- Enrollment target
Study Summary
Primary objectives: 1. To comprehensively characterize steady state stereoselective pharmacokinetics of bupropion and its primary and secondary metabolites in healthy volunteers 2. To prospectively determine the time course (onset), extent and offset of CYP2D6 inhibition in relation to the pharmacokinetic profiles of bupropion and metabolites.
Interventions
- DRUG Bupropion
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2018-06-05 |
| Est. Completion | 2019-05-01 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03420469
The ClinicalTrials.gov registry entry for NCT03420469 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Indiana University, which has 890 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Bupropion is the first listed.
NCT03420469 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03420469 about?
NCT03420469 is a clinical study titled "Bupropion Stereoselective Disposition and CYP2D6-mediated Drug Interactions in Healthy Volunteers". Primary objectives: 1. To comprehensively characterize steady state stereoselective pharmacokinetics of bupropion and its primary and secondary metabolites in healthy volunteers 2. To prospectively determine the time course (onset), extent and offset of CYP2D6 inhibition in relation to the pharmaco...
What is the current status of trial NCT03420469?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 28 participants. The study started on 2018-06-05. Estimated completion is 2019-05-01.
What interventions are being tested in trial NCT03420469?
The interventions under investigation include: Bupropion (DRUG).
Who is sponsoring clinical trial NCT03420469?
This trial is sponsored by Indiana University, which has 890 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.